Brisbane medical device company Oventus has much pleasure in announcing the appointment of Dr Mel Bridges as Chairman.
Mel Bridges has highly respected achievements in the biotechnology and life sciences sector and was the co-founder of ASX-listed Brisbane biotechnology companies Pan Bio and Impedimed.
He has served on the boards of ASX-listed Alchemia (Chairman), Tissue Therapies, Benetic and Parma Corporation.
Oventus Clinical Director and founder Dr Chris Hart said, “We are honoured to have someone of the calibre of Mel Bridges as Chairman of Oventus and believe he is the right person to take us through our next phase of growth as we plan for an international expansion of the business next year.
“Mel is a perfect fit for Oventus having over 30 years’ experience building successful, international life science, diagnostic and medical device companies.
“This experience will help guide us tremendously as we endeavour to become a world leader in the sleep disorder market.”
Mel holds a Bachelor of Science and a Doctorate from the Queensland University of Technology.
He is also a Fellow of the Australian Institute of Company Directors (AICD) and is also on their Council.
During his career he has raised more than $400 million in biotech investment capital.